Status:
COMPLETED
The Nicotinic Cholinergic System and Cognitive Aging
Lead Sponsor:
University of Vermont
Collaborating Sponsors:
Vanderbilt University Medical Center
Conditions:
Healthy Aging
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are ...
Detailed Description
The cholinergic system has been shown to be the primary neurotransmitter system responsible for cognitive symptoms in dementia. While therapeutic benefits are clear in dementia, what remains uncertain...
Eligibility Criteria
Inclusion
- Normal cognition, not demented, no mild cognitive impairment. IQ greater than 80.
Exclusion
- Current use of barbiturates, rifampin, insulin, carbamezepine, oral hypoglycemics, antidepressants, diabetes, or untreated thyroid disease.
- In addition, the following exclusions are specific for the challenge drugs: heavy alcohol or coffee use, significant cardiovascular disease, ischemic heart disease, asthma, chronic obstructive pulmonary disease, active peptic ulcer, hyperthyroidism, pyloric stenosis, narrow angle glaucoma, epilepsy, or current Axis I psychiatric disorders.
- Current use of centrally active drugs and drugs with cholinergic properties. A minimum of 14 days will elapse between discontinuing centrally active or psychoactive agents and this study.
Key Trial Info
Start Date :
October 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT03408574
Start Date
October 1 2016
End Date
January 31 2022
Last Update
May 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont
Burlington, Vermont, United States, 05401